CIGB-300: A promising anti-casein kinase 2 (CK2) peptide for cancer targeted therapy | ||
| dc.conicet.organizacion | No especifíca | |
| dc.conicet.organizacion | No especifíca | |
| dc.conicet.organizacion | No especifíca | |
| dc.conicet.organizacion | No especifíca | |
| dc.conicet.organizacion | Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Oncología Molecular | |
| dc.conicet.organizacion | Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Oncología Molecular | |
| dc.conicet.organizacion | Consejo Nacional de Investigaciones Científicas y Técnicas | |
| dc.conicet.organizacion | No especifíca | |
| dc.conicet.organizacion | No especifíca | |
| dc.conicet.organizacion | No especifíca | |
| dc.conicet.organizacion | Romikin S.a | |
| dc.conicet.organizacion | Romikin S.a | |
| dc.conicet.organizacion | Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Oncología Molecular | |
| dc.conicet.organizacion | Consejo Nacional de Investigaciones Científicas y Técnicas | |
| dc.conicet.organizacion | Romikin S.a | |
| dc.conicet.paginas | 376 | es |
| dc.contributor.author | Perea, Silvio E. | |
| dc.contributor.author | Perera, Yasser | |
| dc.contributor.author | Baladron, Idania | |
| dc.contributor.author | Gonzalez, Lidia | |
| dc.contributor.author | Benavent, Fernando | |
| dc.contributor.author | Farina, Hernán Gabriel | |
| dc.contributor.author | Garcia, Idrián | |
| dc.contributor.author | Rodriguez, Arielis | |
| dc.contributor.author | Reyes, Vilcy | |
| dc.contributor.author | Garcia, Yanelda | |
| dc.contributor.author | Gomez, Roberto | |
| dc.contributor.author | Alonso, Daniel Fernando | |
| dc.contributor.author | Valenzuela, Carmen | |
| dc.date.issued | 2015 | es |
| dc.description.abstract | Over the past few years, the development of CK2 inhibitors using small molecules has emerged as a paradigmatic approach for blocking the enzymatic activity. However, despite successful experimental validation, so far only one of such chemical compounds has entered into clinical trials. Using a different rationale to inhibit CK2, we have developed CIGB-300 as a novel hypothesis-driven peptide targeting the CK2 phosphoacceptor domain instead of the ATP-binding site. Data from in vitro studies have revealed that at least in human cell lines from solid tumors, CIGB-300 binds mainly to and inhibits CK2-mediated phosphorylation of B23/npm. Studies of the molecular and cellular events downstream this interaction have demonstrated that CIGB-300 induces apoptosis in vitro and in vivo, modulating a wide array of proteins involved in cell proliferation, apoptosis, ribosome biogenesis, drug resistance, cell motility, and adhesion among other processes. Accordingly, CIGB-300 has shown synergistic interaction with anticancer drugs, suppressing angiogenesis and exhibiting antimetastatic properties. The pharmacology of this peptide-based drug has already been investigated in cancer patients. Different Phase 1 clinical trials have shown CIGB-300 to be safe and well tolerated and have studied its pharmacokinetics after either local or systemic administration. Remarkably, during a dose-fi nding Phase 2 trial in women with cervical cancer, cohorts receiving CIGB-300 and chemoradiotherapy concomitantly had a higher frequency of complete response than those receiving chemoradiotherapy alone. Taken together, the data presented here summarize all relevant preclinical and clinical fi ndings that make CIGB-300 a promising peptide-based drug for the treatment of cancer patients. | es |
| dc.description.fil | Fil: Perea, Silvio E.. No especifíca; | |
| dc.description.fil | Fil: Perera, Yasser. No especifíca; | |
| dc.description.fil | Fil: Baladron, Idania. No especifíca; | |
| dc.description.fil | Fil: Gonzalez, Lidia. No especifíca; | |
| dc.description.fil | Fil: Benavent, Fernando. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Oncología Molecular; Argentina | |
| dc.description.fil | Fil: Farina, Hernán Gabriel. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Oncología Molecular; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina | |
| dc.description.fil | Fil: Garcia, Idrián. No especifíca; | |
| dc.description.fil | Fil: Rodriguez, Arielis. No especifíca; | |
| dc.description.fil | Fil: Reyes, Vilcy. No especifíca; | |
| dc.description.fil | Fil: Garcia, Yanelda. Romikin S.a; Argentina | |
| dc.description.fil | Fil: Gomez, Roberto. Romikin S.a; Argentina | |
| dc.description.fil | Fil: Alonso, Daniel Fernando. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Oncología Molecular; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina | |
| dc.description.fil | Fil: Valenzuela, Carmen. Romikin S.a; Argentina | |
| dc.format | application/pdf | es |
| dc.identifier.citation | Perea, Silvio E.; Perera, Yasser; Baladron, Idania; Gonzalez, Lidia; Benavent, Fernando; et al.; CIGB-300: A promising anti-casein kinase 2 (CK2) peptide for cancer targeted therapy; Springer; 2015; 281-298 | es |
| dc.identifier.institucional | CONICET | |
| dc.identifier.isbn | 978-3-319-14543-3 | es |
| dc.identifier.repo | CONICET Digital | |
| dc.identifier.uri | http://hdl.handle.net/11336/270480 | |
| dc.journal.ciudad | New York | es |
| dc.journal.pagination | 281-298 | es |
| dc.journal.pais | Estados Unidos | es |
| dc.language.iso | eng | es |
| dc.publisher | Springer | es |
| dc.relation.alternativeid | info:eu-repo/semantics/altIdentifier/url/https://link.springer.com/book/10.1007/978-3-319-14544-0 | |
| dc.rights | info:eu-repo/semantics/restrictedAccess | * |
| dc.rights.uri | https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ | * |
| dc.source.titulo | Protein Kinase CK2 Cellular Function in Normal and Disease States | es |
| dc.subject | CK2 | es |
| dc.subject | CK2 INHIBITORS | es |
| dc.subject | B23 | es |
| dc.subject | APOPTOSIS | es |
| dc.subject.classification | Bioquímica y Biología Molecular | es |
| dc.subject.classification | Ciencias Biológicas | es |
| dc.subject.classification | CIENCIAS NATURALES Y EXACTAS | es |
| dc.title | CIGB-300: A promising anti-casein kinase 2 (CK2) peptide for cancer targeted therapy | es |
| dc.type | info:eu-repo/semantics/publishedVersion | |
| dc.type | info:eu-repo/semantics/bookPart | |
| dc.type | info:ar-repo/semantics/parte de libro | |
Archivos
Bloque original
Cargando...
- Nombre:
- CONICET_Digital_Nro.63270441-58c9-409c-bd90-05db2b203a2e_W.pdf
- Tamaño:
- 446.29 KB
- Formato:
- Adobe Portable Document Format
- Descripción: